Literature DB >> 22901591

Correlation of magnetic resonance imaging tumor volume with histopathology.

Baris Turkbey1, Haresh Mani2, Omer Aras1, Ardeshir R Rastinehad3, Vijay Shah4, Marcelino Bernardo5, Thomas Pohida6, Dagane Daar1, Compton Benjamin3, Yolanda L McKinney1, W Marston Linehan3, Bradford J Wood7, Maria J Merino2, Peter L Choyke1, Peter A Pinto8.   

Abstract

PURPOSE: The biology of prostate cancer may be influenced by the index lesion. The definition of index lesion volume is important for appropriate decision making, especially for image guided focal treatment. We determined the accuracy of magnetic resonance imaging for determining index tumor volume compared with volumes derived from histopathology.
MATERIALS AND METHODS: We evaluated 135 patients (mean age 59.3 years) with a mean prostate specific antigen of 6.74 ng/dl who underwent multiparametric 3T endorectal coil magnetic resonance imaging of the prostate and subsequent radical prostatectomy. Index tumor volume was determined prospectively and independently by magnetic resonance imaging and histopathology. The ellipsoid formula was applied to determine histopathology tumor volume, whereas manual tumor segmentation was used to determine magnetic resonance tumor volume. Histopathology tumor volume was correlated with age and prostate specific antigen whereas magnetic resonance tumor volume involved Pearson correlation and linear regression methods. In addition, the predictive power of magnetic resonance tumor volume, prostate specific antigen and age for estimating histopathology tumor volume (greater than 0.5 cm(3)) was assessed by ROC analysis. The same analysis was also conducted for the 1.15 shrinkage factor corrected histopathology data set.
RESULTS: There was a positive correlation between histopathology tumor volume and magnetic resonance tumor volume (Pearson coefficient 0.633, p <0.0001), but a weak correlation between prostate specific antigen and histopathology tumor volume (Pearson coefficient 0.237, p = 0.003). On linear regression analysis histopathology tumor volume and magnetic resonance tumor volume were correlated (r(2) = 0.401, p <0.00001). On ROC analysis AUC values for magnetic resonance tumor volume, prostate specific antigen and age in estimating tumors larger than 0.5 cm(3) at histopathology were 0.949 (p <0.0000001), 0.685 (p = 0.001) and 0.627 (p = 0.02), respectively. Similar results were found in the analysis with shrinkage factor corrected tumor volumes at histopathology.
CONCLUSIONS: Magnetic resonance imaging can accurately estimate index tumor volume as determined by histology. Magnetic resonance imaging has better accuracy in predicting histopathology tumor volume in tumors larger than 0.5 cm(3) than prostate specific antigen and age. Index tumor volume as determined by magnetic resonance imaging may be helpful in planning treatment, specifically in identifying tumor margins for image guided focal therapy and possibly selecting better active surveillance candidates.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22901591      PMCID: PMC5462598          DOI: 10.1016/j.juro.2012.06.011

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds.

Authors:  Vijay Shah; Thomas Pohida; Baris Turkbey; Haresh Mani; Maria Merino; Peter A Pinto; Peter Choyke; Marcelino Bernardo
Journal:  Rev Sci Instrum       Date:  2009-10       Impact factor: 1.523

2.  [Active surveillance for prostate cancer: usefulness of endorectal MR at 1.5 Tesla with pelvic phased array coil in detecting significant tumors].

Authors:  F Luyckx; P Hallouin; C Barré; G Aillet; P Chauveau; J-F Hétet; O Bouchot; J Rigaud
Journal:  Prog Urol       Date:  2010-09-17       Impact factor: 0.915

3.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.

Authors:  Huadong Miao; Hiroshi Fukatsu; Takeo Ishigaki
Journal:  Eur J Radiol       Date:  2006-11-07       Impact factor: 3.528

4.  Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers.

Authors:  Masanori Noguchi; Thomas A Stamey; John E McNeal; Rosalie Nolley
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

5.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens.

Authors:  Alphaeus M Wise; Thomas A Stamey; John E McNeal; John L Clayton
Journal:  Urology       Date:  2002-08       Impact factor: 2.649

6.  Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection.

Authors:  Andrew B Rosenkrantz; Jeffry Neil; Xiangtian Kong; Jonathan Melamed; James S Babb; Samir S Taneja; Bachir Taouli
Journal:  AJR Am J Roentgenol       Date:  2010-02       Impact factor: 3.959

7.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

Authors:  Iclal Ocak; Marcelino Bernardo; Greg Metzger; Tristan Barrett; Peter Pinto; Paul S Albert; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

8.  Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy.

Authors:  John F Ward; Hiroyuki Nakanishi; Louis Pisters; R Joseph Babaian; Patricia Troncoso
Journal:  BJU Int       Date:  2009-02-10       Impact factor: 5.588

Review 9.  Pathology of prostate cancer and focal therapy ('male lumpectomy').

Authors:  Roberta Mazzucchelli; Marina Scarpelli; Liang Cheng; Antonio Lopez-Beltran; Andrea B Galosi; Ziya Kirkali; Rodolfo Montironi
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

10.  Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; J O Barentsz
Journal:  AJR Am J Roentgenol       Date:  1996-04       Impact factor: 3.959

View more
  53 in total

1.  Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.

Authors:  Jonathan B Bloom; Graham R Hale; Samuel A Gold; Kareem N Rayn; Clayton Smith; Sherif Mehralivand; Marcin Czarniecki; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto
Journal:  J Urol       Date:  2019-01       Impact factor: 7.450

2.  Assessment of change in prostate volume and shape following surgical resection through co-registration of in-vivo MRI and fresh specimen ex-vivo MRI.

Authors:  C Orczyk; S S Taneja; H Rusinek; A B Rosenkrantz
Journal:  Clin Radiol       Date:  2014-07-22       Impact factor: 2.350

3.  A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation.

Authors:  Andriy Fedorov; Jacob Fluckiger; Gregory D Ayers; Xia Li; Sandeep N Gupta; Clare Tempany; Robert Mulkern; Thomas E Yankeelov; Fiona M Fennessy
Journal:  Magn Reson Imaging       Date:  2014-01-21       Impact factor: 2.546

4.  MRI-TRUS fusion for electrode positioning during irreversible electroporation for treatment of prostate cancer.

Authors:  Alexander D J Baur; Federico Collettini; Judith Enders; Andreas Maxeiner; Vera Schreiter; Carsten Stephan; Bernhard Gebauer; Bernd Hamm; Thomas Fischer
Journal:  Diagn Interv Radiol       Date:  2017 Jul-Aug       Impact factor: 2.630

5.  Diagnosis of transition zone prostate cancer using T2-weighted (T2W) MRI: comparison of subjective features and quantitative shape analysis.

Authors:  Satheesh Krishna; Nicola Schieda; Matthew Df McInnes; Trevor A Flood; Rebecca E Thornhill
Journal:  Eur Radiol       Date:  2018-08-13       Impact factor: 5.315

Review 6.  Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up.

Authors:  Berrend G Muller; Willemien van den Bos; Peter A Pinto; Jean J de la Rosette
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

Review 7.  Multiparametric MRI in prostate cancer management.

Authors:  Linda M Johnson; Baris Turkbey; William D Figg; Peter L Choyke
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

Review 8.  Prostate biopsy for the interventional radiologist.

Authors:  Cheng William Hong; Hayet Amalou; Sheng Xu; Baris Turkbey; Pingkun Yan; Jochen Kruecker; Peter A Pinto; Peter L Choyke; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2014-02-26       Impact factor: 3.464

9.  Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold?

Authors:  Julie Y An; Stephanie A Harmon; Sherif Mehralivand; Marcin Czarniecki; Clayton P Smith; Julie A Peretti; Bradford J Wood; Peter A Pinto; Peter L Choyke; Joanna H Shih; Baris Turkbey
Journal:  Abdom Radiol (NY)       Date:  2018-12

10.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.